
|Videos|November 13, 2020
(AAO) Genentech provides update on presentations, product portfolio
Author(s)OT Staff Reports, Sheryl Stevenson
Chris Brittain, MBBS, BSc, MBA, MRCOphth, vice president and global head of ophthalmology product development for Genentech, provides an overview of the company’s podium presentations from the PDS with ranibizumab to faricimab.
Advertisement
Chris Brittain, MBBS, BSc, MBA, MRCOphth, vice president and global head of ophthalmology product development for Genentech, provides an overview of some of the company’s podium presentations from the Port Delivery System with ranibizumab to the novel pipeline molecule, faricimab.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
ARPA-H funds tear-duct biosensor system for dry eye, systemic disease
2
Memento Medicines launches with $93 million Series A to advance Tie2-activating bispecific for retinal disease
3
First patient dosed in phase 3 pivotal cohort of LIGHTHOUSE trial evaluating ATSN-201 for X-linked retinoschisis
4
NCX 470 gains positive regulatory feedback in China ahead of US NDA submission
5


























